

# The FDA Pharmacy Compounding Advisory Committee recently voted to recommend 6 major peptides (including BPC-157, KPV, and TB-500) for the 503A bulk substances list.

JULY 23-24



## Jim LaValle, RPh, CCN, MT

Chair, International Peptide Society

Chair, A4M Peptide Certification Program

Member, A4M Scientific Committee

Clinical Co-Chair A4M

On July 23-24, the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptide substances. The committee voted to recommend six **BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax** for inclusion on the Section 503A list of substances that traditional compounding pharmacies may use to prepare medications for individual patients pursuant to a valid prescription. **Emideltide (DSIP)** was the only substance not recommended.

I was present throughout the proceedings and had the privilege of providing expert testimony on the general manufacturing of peptides, quality characterization, safety, clinical relevance, and responsible use of peptide therapies.

This was a meaningful and encouraging development, but it is important that we interpret it accurately.

**The committee's vote was a recommendation not a final FDA approval.** It did not immediately change the legal or regulatory status of these peptides, nor did it authorize pharmacies to begin compounding substances that are not currently permitted. The FDA must still complete its review and move through the formal rulemaking process, which could extend into 2027 and beyond.

Even so, the significance of the vote should not be overlooked. It represents an important step toward establishing a more legitimate, evidence-informed, and appropriately regulated pathway for compounded peptide therapies.

As this field continues to evolve, the clinicians who will be best positioned to lead are those who understand not only the potential benefits of peptides, but also their mechanisms of action, patient-selection criteria, safety considerations, dosing principles, quality standards, and changing regulatory status.

That is why credible education matters now more than ever.

For more than a decade, A4M and the International Peptide Society have worked to provide clinicians with balanced, evidence-informed peptide education not hype, oversimplified protocols, or fragmented information from social media, but the scientific and clinical foundation required to make thoughtful decisions for individual patients.

After more than four decades in clinical practice and practitioner education, I believe strongly that the future of peptide therapy depends on responsible clinical leadership. Patient access must be accompanied by appropriate medical oversight, high-quality compounding standards, ongoing monitoring, and clinicians who are properly trained to use these therapies ethically and effectively.

Whether you are already incorporating approved peptides into your practice or preparing for where this field is headed, now is the time to deepen your knowledge.

The **A4M Peptide Therapy Certification** is designed to help clinicians navigate this rapidly changing environment with greater clarity and confidence. The program provides a practical understanding of peptide science, clinical application, safety, quality, and regulatory considerations so you can evaluate and integrate these therapies responsibly as the field progresses.

**Explore the Peptide  
Therapy Certification**